ABBV-951
AssetAlso called Foscarbidopa, Foslevodopa, LDP/CDP
Prodrugs supply levodopa and carbidopa, restoring brain dopamine while inhibiting peripheral levodopa breakdown.
- Stage
- Approved
- Modality
- Small molecule
- Target
- ADRB1
- 2
- Indications
- 7
- Trials
- 1
- Developer
Indications
2No named disease
Approved, 2024
Parkinson's disease
Phase 3, Completed, NCT04379050, clinicaltrials.gov, Nov 10, 2026
In the full profile
- Target and mechanism1
- Owner and partners1
- Trials7
- Evidence for its targets1
- Competitors12
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.